Comment on Rilstone et al: A Randomized Controlled Trial Assessing the Impact of Continuous Glucose Monitoring with a Predictive Hypoglycemia Alert Function on Hypoglycemia in Physical Activity for People with Type 1 Diabetes (PACE)

Abstract

Get full access to this article

View all access options for this article.

References

Rilstone

, Oliver

, Godsland

, et al. A randomized controlled trial assessing the impact of continuous glucose monitoring with a predictive hypoglycemia alert function on hypoglycemia in physical activity for people with type 1 diabetes (PACE). Diabetes Technol Ther, 2024; 26(2):95–102; doi: 10.1089/dia.2023.0376

Dexcom G7 User Guide. 2023. Available from: https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G7-CGM-Users-Guide.pdf

Farfel

, Liberman

, Yackobovitch-Gavan

, et al. Executive functions and adherence to continuous glucose monitoring in children and adolescents with type 1 diabetes. Diabetes Technol Ther, 2020; 22(4):265–270; doi: 10.1089/dia.2019.0341

Food and Drug Administration. Evaluation of automatic Class III designation for Dexcom G6 continuous glucose monitoring system. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170088.pdf [Last accessed: May 30, 2024 ].

Visser

, Charleer

, Fieuws

, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): A 6-month, prospective, multicentre, randomised controlled trial. Lancet, 2021; 397(10291):2275–2283; doi: 10.1016/s0140-6736(21)00789-3